Bayer and PCF launch darolutamide challenge awards for prostate cancer
The two projects will be awarded $1m each to support their clinical investigations
Read More
Tag: darolutamide
SMC recommends Bayer’s cancer treatments for NHS Scotland use
Eligible patients in Scotland will now have access to Nubeqa and Stivarga
Read More
Bayer, Orion win FDA priority review for darolutamide in prostate cancer
Darolutamide is an investigational, non-steroidal androgen receptor antagonist.
Read More
Darolutamide submitted for EU approval
Orion Corporation and Bayer have submitted a marketing application in Europe for use of darolutamide in patients with a certain type of prostate cancer.
Read More
Darolutamide shows promise for treatment of prostate cancer
Orion’s and Bayer’s darolutamide has shown substantial efficacy in the treatment of prostate cancer.
Read More
- MRM Health collaborates with Oncode Institute and Netherlands Cancer Institute
- Sobi to acquire Arthrosi Therapeutics, strengthening gout treatment pipeline
- Lindus Health and Quotient Sciences announce strategic partnership to accelerate drug development
- Title21 Health Solutions joins the Blood and Cells Advocacy Roster
- NADMED launches $30,000 metabolomics research award
